Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2023

Open Access 01-12-2023 | Adenovirus | Research

Severe pediatric adenoviral pneumonia combined with invasive pulmonary aspergillosis

Authors: Shuihua Huang, Shengxin Zhang, Lin Yuan, Zhiqiang Zhuo, Xingdong Wu

Published in: BMC Pulmonary Medicine | Issue 1/2023

Login to get access

Abstract

Background

This study aimed to analyze the clinical characteristics of severe pediatric adenoviral pneumonia combined with invasive pulmonary aspergillosis.

Methods

We retrospectively analyzed the clinical data of five children clinically diagnosed with severe adenoviral pneumonia combined with invasive pulmonary aspergillosis at Xiamen Children’s Hospital.

Results

These five children included one boy and four girls, with ages of onset ranging from 8 months and 15 days to 2 years and 2 months. All of them had fever with a mean duration of 11–35 days and cough. Pulmonary imaging was performed, which revealed solid pulmonary opacification in all five children, pleural effusion in two children, and emphysema and multiple small cavity formations in one child. Multiple microbiological tests were performed on the 5 children, and adenovirus was positive in the alveolar lavage fluid for the first time, and aspergillus culture was positive in the second test. On tracheoscopy, the bronchial mucosa was seen to be congested and edematous or pale and eroded; white moss-like material was seen adhering to the tracheal wall or even blocking the airway. The five children were treated with a combination of two or more broad-spectrum antimicrobials, glucocorticoids, and gamma globulins and underwent bronchoscopy. Voriconazole was added in the treatment regimen after the diagnosis of aspergillosis (28–34 days of treatment). Four of the children were discharged in good condition with a mean total length of hospital stay of 17–47 days. The other child leave against medical advice. Follow-up 3–5 months after discharge showed that one child had been cured; two children had developed obliterative bronchiolitis; one child had developed bronchiectasis; and the remaining child who had been discharged spontaneously was not contactable via telephone.

Conclusions

Immune disorders and antibiotic and steroid treatments for adenovirus infection are high-risk factors for secondary invasive pulmonary aspergillosis in children. Prolonged fever and cough are the main manifestations, but which lack specificity, and bronchoscopic mucosal-specific injury evaluation and alveolar lavage fluid culture are helpful in the diagnosis of aspergillosis. The long-term prognosis of severe pediatric adenoviral pneumonia combined with invasive pulmonary aspergillosis maybe poor.
Literature
5.
go back to reference Donnelly JP, Chen SC, Kauffman CA et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020 Sep 12;71(6):1367–1376. doi: https://doi.org/10.1093/cid/ciz1008. Donnelly JP, Chen SC, Kauffman CA et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020 Sep 12;71(6):1367–1376. doi: https://​doi.​org/​10.​1093/​cid/​ciz1008.
6.
go back to reference Yamei Hu, Zaifang J, Kunling S et al. Zhu Futang practical Pediatrics [M]. Rev. 8. Beijing People’s Health Press, 2015:1253. Yamei Hu, Zaifang J, Kunling S et al. Zhu Futang practical Pediatrics [M]. Rev. 8. Beijing People’s Health Press, 2015:1253.
8.
go back to reference Rajkumar,Veena, et al. Risk factors for severe adenovirus infection in children during an outbreak in Singapore [J]. Ann Acad Med Singap. 2015;44(2):50–9.CrossRefPubMed Rajkumar,Veena, et al. Risk factors for severe adenovirus infection in children during an outbreak in Singapore [J]. Ann Acad Med Singap. 2015;44(2):50–9.CrossRefPubMed
10.
go back to reference Sun J, Xiao Y, Zhang M et al. Serum inflammatory markers in patients with adenovirus respiratory infection [J]. med Sci Monit, 2018, 24: 3848–3855. DOI.10.12659/MSM.910692. Sun J, Xiao Y, Zhang M et al. Serum inflammatory markers in patients with adenovirus respiratory infection [J]. med Sci Monit, 2018, 24: 3848–3855. DOI.10.12659/MSM.910692.
14.
go back to reference Technical Expert Group of Pediatric Respiratory Endoscopy Diagnosis and Treatment of Talent Exchange Service Center of National Health Commission, Children of Chinese Medical Doctor Association, Endoscopy Professional Committee of Medical Doctor Branch, Pediatric Respiratory Endoscopy Professional Committee of Endoscopist Branch of Chinese Medical Doctor Association, etc. Chinese Guidelines for Pediatric flexible bronchoscopy (2018 edition). Chin J Practical Pediatr Clin Pract. 2018;33(13):983–9. https://doi.org/10.3760/cma.j.issn.2095-428X.2018.13.006.CrossRef Technical Expert Group of Pediatric Respiratory Endoscopy Diagnosis and Treatment of Talent Exchange Service Center of National Health Commission, Children of Chinese Medical Doctor Association, Endoscopy Professional Committee of Medical Doctor Branch, Pediatric Respiratory Endoscopy Professional Committee of Endoscopist Branch of Chinese Medical Doctor Association, etc. Chinese Guidelines for Pediatric flexible bronchoscopy (2018 edition). Chin J Practical Pediatr Clin Pract. 2018;33(13):983–9. https://​doi.​org/​10.​3760/​cma.​j.​issn.​2095-428X.​2018.​13.​006.CrossRef
Metadata
Title
Severe pediatric adenoviral pneumonia combined with invasive pulmonary aspergillosis
Authors
Shuihua Huang
Shengxin Zhang
Lin Yuan
Zhiqiang Zhuo
Xingdong Wu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2023
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-023-02447-y

Other articles of this Issue 1/2023

BMC Pulmonary Medicine 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.